Skip to main content

Advertisement

SpringerLink
Log in

Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To study the effect on untreated fellow eyes of eyes treated with an intravitreal injection of bevacizumab.

Methods

Bevacizumab (1.25 mg/0.05 ml) was injected into the vitreous cavity of one eye (the first eye) as a preoperative adjunctive therapy for proliferative diabetic retinopathy; vitrectomy was performed 1 week later. Immediately after vitrectomy, bevacizumab (1.25 mg/0.05 ml) was injected into the fellow eye (the second eye) followed by vitrectomy 1 week later. Aqueous humor samples were obtained from both eyes in five cases just before intravitreal injection of bevacizumab and just before vitrectomy 1 week later. Vascular endothelial growth factor (VEGF) concentrations in the aqueous humor were measured by enzyme-linked immunosorbent assay (ELISA).

Results

VEGF concentrations in the aqueous humor of the first eyes ranged from 146 to 398 pg/ml (mean, 302±100 pg/ml) before intravitreal injection of bevacizumab; 1 week later, the VEGF concentrations in the injected eyes were less than 31 pg/ml, the lower limit of the ELISA, in all cases (p<0.001). The concentrations in the uninjected fellow eyes ranged from 181 to 551 pg/ml (mean, 382±119 pg/ml).

Conclusions

There seemed to be no or a minimal effect of the intravitreal injections of bevacizumab on the uninjected fellow eyes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487, doi:10.1056/NEJM199412013312203

    Article  PubMed  CAS  Google Scholar 

  2. Avery RL, Pearlman J, Pieramici D, Rabena MD, Castellarin AA, Nasir MA et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113(10):1695–1705, doi:10.1016/j.ophtha.2006.05.064

    Article  PubMed  Google Scholar 

  3. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26(3):275–278, doi:10.1097/00006982-200603000-00004

    Article  PubMed  Google Scholar 

  4. Bakri SJ, Donaldson MJ, Link TP (2006) Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye 20(12):1474–1475, doi:10.1038/sj.eye.6702364

    Article  PubMed  CAS  Google Scholar 

  5. Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab inpatients with proliferative diabetic retinopathy. Am J Ophthalmol 142(1):155–158, doi:10.1016/j.ajo.2006.02.015

    Article  PubMed  CAS  Google Scholar 

  6. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group (2006) Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 142(1):158–160, doi:10.1016/j.ajo.2006.02.045

    Article  PubMed  CAS  Google Scholar 

  7. Friedlander SM, Welch RM (2006) Vanishing disc neovascularization following intravitreal bevacizumab (Avastin) injection. Arch Ophthalmol 124(9):365, doi:10.1001/archopht.124.9.1365

    Article  Google Scholar 

  8. Chen E, Park CH (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26(6):699–700, doi:10.1097/01.iae.0000225351.87205.69

    Article  PubMed  Google Scholar 

  9. Mason JO 3rd, Nixon PJ, White MF (2006) Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142(4):685–688, doi:10.1016/j.ajo.2006.04.058

    Article  PubMed  CAS  Google Scholar 

  10. Sawada O, Kawamura H, Kakinoki M, Ohji M (2007) Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 125(10):1363–1366, doi:10.1001/archopht.125.10.1363

    Article  PubMed  CAS  Google Scholar 

  11. Funatsu H, Yamashita H, Noma H, Miura T, Nakamura S, Sakata K et al (2005) Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 243(1):3–8, doi:10.1007/s00417-004-0950-7

    Article  PubMed  CAS  Google Scholar 

  12. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114(5):855–859, doi:10.1016/j.ophtha.2007.01.017

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shiga University of Medical Science, Seta Tukinowacho, Otsu, Shiga, 520-2192, Japan

    Osamu Sawada, Hajime Kawamura, Masashi Kakinoki & Masahito Ohji

Authors
  1. Osamu Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hajime Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masashi Kakinoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahito Ohji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osamu Sawada.

Additional information

The authors have no proprietary interest in any aspect of this study.

The study was partially supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (#18591915) and a grant from the Ministry of Health, Labour and Welfare.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sawada, O., Kawamura, H., Kakinoki, M. et al. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 246, 1379–1381 (2008). https://doi.org/10.1007/s00417-008-0874-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0874-8

Keywords

Search

Navigation